Arjuna Capital Grows Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Arjuna Capital increased its Thermo Fisher Scientific stake by 64.5% in the fourth quarter, adding 2,582 shares to bring its total to 6,583 shares worth about $3.8 million.
• Thermo Fisher continues to see heavy institutional ownership, with major holders like Vanguard and Capital World Investors also boosting their positions; institutions now own 89.23% of the stock.
• The company reported better-than-expected quarterly results, with EPS of $5.44 and revenue of $11.01 billion, while also raising its quarterly dividend to $0.47 per share from $0.43.

Arjuna Capital grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 64.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,583 shares of the medical research company's stock after acquiring an additional 2,582 shares during the quarter. Thermo Fisher Scientific comprises about 0.9% of Arjuna Capital's portfolio, making the stock its 24th largest position. Arjuna Capital's holdings in Thermo Fisher Scientific were worth $3,815,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Thermo Fisher Scientific by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock worth $19,778,774,000 after purchasing an additional 288,296 shares during the last quarter. Capital World Investors boosted its holdings in shares of Thermo Fisher Scientific by 7.4% in the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company's stock valued at $4,988,132,000 after buying an additional 706,572 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Thermo Fisher Scientific by 21.0% in the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company's stock valued at $2,874,069,000 after buying an additional 1,028,125 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Thermo Fisher Scientific by 54.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company's stock valued at $1,732,422,000 after purchasing an additional 1,262,967 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in Thermo Fisher Scientific by 5.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,087,666 shares of the medical research company's stock worth $1,789,148,000 after buying an additional 150,668 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares of the company's stock, valued at $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 2.2%

TMO stock opened at $438.16 on Friday. The company's 50 day moving average price is $486.00 and its 200 day moving average price is $542.12. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The firm has a market capitalization of $162.83 billion, a price-to-earnings ratio of 24.09, a PEG ratio of 1.98 and a beta of 0.88. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm's quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the company posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were issued a dividend of $0.47 per share. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Friday, March 13th. Thermo Fisher Scientific's dividend payout ratio is 10.34%.

Analyst Ratings Changes

TMO has been the subject of a number of recent research reports. Royal Bank Of Canada set a $490.00 price target on shares of Thermo Fisher Scientific and gave the stock a "sector perform" rating in a research report on Thursday. Morgan Stanley reaffirmed an "overweight" rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Saturday, May 9th. UBS Group reissued a "neutral" rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Finally, Barclays reduced their price objective on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating on the stock in a report on Tuesday, April 14th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $616.10.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.